Successful drug innovation grows from a deep appreciation of disease pathophysiology and ingenuity - something that we have in spades.
It is further driven by a desire to make a difference - We are driven to make a profound difference in the treatment of cardiovascular, pulmonary, and metabolic diseases. We believe that we will change how diseases like heart failure, asthma, COPD, pulmonary hypotension, diabetes, and others will be treated in the future.
Our collective years of experience in biotechnology and developing peptide-based therapies has given us an unparalleled understanding of the pharmacology of our target peptide-based therapeutics and the epidemiology of the underlying diseases.
Our work is supported by world-class advisors and collaborators who are aligned with our vision to bring life-changing therapies to the market.
Antlia Bioscience, Inc. is a biotech start-up developing novel and transformational disease-modifying, long-acting analogs of selected endogenous human peptides to treat cardiovascular, pulmonary, and metabolic diseases.
The Prior Technology Hurdle: Previous attempts at using the native peptides as long-term use therapeutics have failed because peptides have short plasma half-lives (minutes) and require delivery by continuous intravenous infusion to maintain plasma levels within narrow therapeutic windows. Consequently, their therapeutic use is exceptionally limited.
Antlia Bioscience’s Solution: Long-Acting Peptide Analogs (LAPA):
Starting with native peptides that have existing pre-clinical and clinical data supporting their potential therapeutic use, we apply a novel and proprietary process called PASylation®and develop long-acting synthetic analogs that allow us to:
1. Extend the natural half-life of the peptide from minutes to a week (or longer) without materially impacting the hormone’s pharmacological activity by maintaining the native peptide amino-acid sequence and structure.
2. Optimize the pharmacokinetics of the peptide so that a once-weekly (or longer interval) subcutaneous injection of a low dose and small dose volume will provide plasma levels that are maintained within the optimal therapeutic range providing optimal safety and efficacy.
3. Expand the use of peptide outside of the acute care setting as a potential continuous therapy for multiple chronic disease indications.
Be bold enough to think outside of the box
Be bold enough to believe
Be bold enough to follow through
How Do We Treat Each Other?
How Do We Do Our Work?
Why Do We Do This Work?
Copyright © 2021 Antlia Bioscience, Inc. - All Rights Reserved.